Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?
JAMA Neurol
.
2021 Jul 1;78(7):787-788.
doi: 10.1001/jamaneurol.2021.0764.
Authors
Eva M M Strijbis
1
,
Anne Kerbrat
2
,
John R Corboy
3
Affiliations
1
MS Center Amsterdam, Amsterdam UMC, Location VUmc, Amsterdam, the Netherlands.
2
Department of Neurology, Rennes University Hospital, Rennes, France.
3
Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado, Denver.
PMID:
33871561
DOI:
10.1001/jamaneurol.2021.0764
No abstract available
MeSH terms
Disease Progression
Humans
Immunosuppressive Agents / therapeutic use*
Multiple Sclerosis / drug therapy*
Multiple Sclerosis, Relapsing-Remitting / drug therapy
Withholding Treatment
Substances
Immunosuppressive Agents